secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ionetix Corp / DE / (—)
CIK:        0002108121
Form:       8-K
Filed at:   2026-05-26T14:00:15+00:00
Accession:  0001213900-26-060830
Event type: regulatory
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ionetix receives FDA approval for Gallium Ga-68 gozetotide (PSMA-11) ANDA
-------------------------------------------------------------------------

- FDA approved Ionetix's Abbreviated New Drug Application for Gallium Ga-68 gozetotide, a PET diagnostic agent.
- First commercial drug manufacturer to receive ANDA approval for this drug.
- Indicated for PSMA-PET imaging to detect prostate cancer lesions in men with suspected metastasis or recurrence.
- Product supplied as single-dose capped syringe (~8-10mL) with three-hour expiration from end of synthesis.
- Expands Ionetix's portfolio in PET diagnostics; company plans to serve underserved areas via existing multi-site PET facility network.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2108121/000121390026060830/0001213900-26-060830-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2108121/000121390026060830/ea0292072-8k_ionetix.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-060830

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer